A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

The introduction of biological agents drastically changed the treatment paradigm of inflammatory arthritides, ameliorating the natural history of the diseases but concomitantly increasing the drug costs due to the manufacturing process. On this concern, biosimilar drugs may represent a valid option...

Descripción completa

Detalles Bibliográficos
Autores principales: Becciolini, Andrea, Raimondo, Maria Gabriella, Crotti, Chiara, Agape, Elena, Biggioggero, Martina, Favalli, Ennio Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500511/
https://www.ncbi.nlm.nih.gov/pubmed/28721016
http://dx.doi.org/10.2147/DDDT.S138515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500511/
https://www.ncbi.nlm.nih.gov/pubmed/28721016
http://dx.doi.org/10.2147/DDDT.S138515

Ejemplares similares